After treatment with the 7 + 3 regimens, there was no significant difference in TFRC expression in AML cells between the complete remission (CR) group and the noncomplete remission (Non-CR) group (GSE103424 and GSE164894; Additional file 1: Fig. S5e, f). This evidence concerns the gene TFRC and acute myeloid leukemia.